Black Diamond Therapeutics (BDTX) Cash from Financing Activities (2019 - 2026)

Black Diamond Therapeutics (BDTX) has 8 years of Cash from Financing Activities data on file, last reported at -$185000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 678.12% year-over-year to -$185000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$363000.0 (down 101.69% YoY) and the FY2025 annual result came in at -$146000.0, down 100.57% from the prior year.
• Cash from Financing Activities grew to -$185000.0 in Q1 2026, from -$196000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $71.9 million in Q3 2023 to a low of -$252000.0 in Q3 2024.
• A 5-year average of $6.5 million and a median of $51000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 138221.15% — and 2026, when it plunged 678.12%.
• Tracing BDTX's Cash from Financing Activities over 5 years: stood at -$28000.0 in 2022, then sank by 64.29% to -$46000.0 in 2023, then jumped by 732.61% to $291000.0 in 2024, then slumped by 167.35% to -$196000.0 in 2025, then increased by 5.61% to -$185000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$185000.0 (Q1 2026), -$196000.0 (Q4 2025), and $134000.0 (Q3 2025), per Business Quant data.